

November 26, 2013

Alberta Securities Commission
British Columbia Securities Commission
Ontario Securities Commission
TSX Venture Exchange

Re: Mercury Capital II (“Mercury”):

Dear Sirs/Mesdames

We refer to the filing statement of Mercury dated November 26, 2013 relating to the Qualifying Transaction involving Revive Therapeutics Inc. (the “Filing Statement”).

We consent to being named in and to the use, through inclusion in the above-mentioned Filing Statement, of our report dated May 22, 2013 to the directors of Mercury on the following financial statements:

- statements financial position of Mercury as at March 31, 2013 and 2012 ;
- statements of comprehensive loss, changes in shareholders’ equity (deficiency) and cash flows for the year ended March 31, 2013 and for the period from March 27, 2012 (date of incorporation) to March 31, 2012; and
- Notes, comprising a summary of significant accounting policies and other information.

We report that we have read the Filing Statement and all information therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statements upon which we have reported or that are within our knowledge as a result of our audit or examination of such financial statements. We have complied with Canadian generally accepted standards for an auditor’s consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the Filing Statement as these terms are described in the CPA Canada Handbook – Assurance.

Yours truly,

MSCM LLP

MSCM LLP